Cost-Effectiveness of Earlier Diagnosis of Fibrotic Interstitial Lung Diseases (Fibrotic ILDs) and Earlier Treatment of Its Progressive Form, Progressive Pulmonary Fibrosis (PPF)

Interstitial Lung DiseaseFurther Publications

The importance of considering progression speed in systemic sclerosis-associated interstitial lung diseases: application of 2022 and 2024 clinical practice guidelines for progressive pulmonary fibrosis, a retrospective cohort study

Respir Res

Roeser A, Brillet PY, Tran Ba S, Caux F, Dhote R, Nunes H, Uzunhan Y

doi: 10.1186/s12931-025-03375-7

COMMENTED

Interstitial Lung Disease

ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease. Developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR)Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG)

★ 3 Recommended by Dr. med. Martin Frey, Faculty Member

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

Eur Respir J

Antoniou KM, Distler O, Gheorghiu AM, Moor CC, Vikse J, Bizymi N, Galetti I, Brown G, Bargagli E, Allanore Y, Corte TJ, Dieudé P, Cottin V, Fisher BA, Fabre A, Giles JT, Kreuter M, Lundberg IE, Poletti V, Maurer B, Renzoni EA, Müller-Ladner U, Strek ME, Sverzellati N, Studenic P, Mohammed J, Nagavci B, Stamm T, Tonia T, Crestani B, Hoffmann-Vold AM

doi: 10.1183/13993003.02533-2024

Interstitial Lung DiseasePulmonary Fibrosis

Effectiveness of antifibrotic treatment in real-world patients with progressive pulmonary fibrosis

Respir Med

Niitsu T, Fukushima K, Komukai S, Yamamoto R, Shiroyama T, Nii T, Takata S, Hashimoto K, Abe Y, Hirata H, Miyake K, Kataoka T, Okudela K, Iwakoshi S, Yanagawa M, Takeuchi N, Takeda Y, Kida H, Kumanogoh A

doi: 10.1016/j.rmed.2025.108347

Interstitial Lung Disease

Rheumatoid arthritis-associated interstitial lung disease: screening, diagnosis, and treatment-an expert group consensus statement

Lancet Respir Med

Solomon JJ, Dieudé P, Matson SM, Lee JS, Rojas-Serrano J, Sebastiani M, Gonzalez A, Demoruelle MK, Hoffman-Vold AM, Kam MLW, Swigris JJ, Sparks JA, Brown KK, Cottin V, Kellermeyer LM, Wilson KC, Waseda Y, Crestani B, Walsh SLF, Poletti V, Doyle T, Koduri G, Kelly C, Danoff S, Dellaripa PF

doi: 10.1016/S2213-2600(26)00094-9

RECOMMENDED

Interstitial Lung DiseasePulmonary Hypertension

Sotatercept for Connective Tissue Disease-Associated Pulmonary Arterial Hypertension with Concomitant Interstitial Lung Disease: Efficacy and Safety Insights

★ 2 Recommended by Dr. med. Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

J Clin Med

Dagher C, Akiki M, Swanson K, Carollo B, Fiscus G, Farber HW, Parikh R

doi: 10.3390/jcm14155177

RECOMMENDED

Interstitial Lung Disease

Clinical utility of lung biopsy in fibrotic interstitial lung disease

★ 3 Recommended by Dr. med. Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Am J Respir Crit Care Med

Mor E, Piciucchi S, Ravaglia C, Aronson K, Poletti V, Hariri LP, Khor YH, Churg A, Collins B, Fabre A, Adegunsoye A, Chung J, Cooper WA, Cottin V, Dotan Y, Hague C, Inoue Y, Jacob J, Martinez F, Podolanczuk AJ, Tomassetti S, Wells AU, Wijsenbeek MS, Yasufuku K, Dominy L, Mcdonald J, Sangari S, Ryerson CJ

doi: 10.1093/ajrccm/aamaf123

Further Publications

The safety and efficacy of secondary spontaneous pneumothorax surgery: Especially in interstitial lung disease and chronic obstructive pulmonary disease

Eur J Cardiothorac Surg

Adachi T, Omasa M, Takehara R, Nakanishi T, Motoyama H

doi: 10.1093/ejcts/ezaf410

Further Publications

Efficacy of Pulmonary Rehabilitation on Patient-Reported Outcomes in Interstitial Lung Disease: A Quasi-Experimental Study

Respir Med

Panwar M, Patnaik SK, Marwah V, Patrikar S, Pandey I, Samiullah M, Parankusam KC

doi: 10.1016/j.rmed.2025.108459

Pulmonary Hypertension

Screening for Pulmonary Hypertension in Interstitial Lung Disease: Preliminary Results from the PHINDER Study

Adv Ther

Zisman D, Sahay S, Bandyopadhyay D, Al-Astal A, Broderick M, Caudell Stamper D, Champion H, DerSarkissian M, Hunsucker M, Lee D, Maher K, Nelsen A, Parikh R, Rahaghi F, Raval A, Thrasher CM, Kulkarni T, Shlobin OA, Kiely DG, Nathan S, Scholand MB

doi: 10.1007/s12325-026-03508-4

Related content

The importance of considering progression speed in systemic sclerosis-associated interstitial lung diseases: application of 2022 and 2024 clinical practice guidelines for progressive pulmonary fibrosis, a retrospective cohort study

Effectiveness of antifibrotic treatment in real-world patients with progressive pulmonary fibrosis

Rheumatoid arthritis-associated interstitial lung disease: screening, diagnosis, and treatment-an expert group consensus statement

Sotatercept for Connective Tissue Disease-Associated Pulmonary Arterial Hypertension with Concomitant Interstitial Lung Disease: Efficacy and Safety Insights

Clinical utility of lung biopsy in fibrotic interstitial lung disease

The safety and efficacy of secondary spontaneous pneumothorax surgery: Especially in interstitial lung disease and chronic obstructive pulmonary disease

Efficacy of Pulmonary Rehabilitation on Patient-Reported Outcomes in Interstitial Lung Disease: A Quasi-Experimental Study

Screening for Pulmonary Hypertension in Interstitial Lung Disease: Preliminary Results from the PHINDER Study